Coping Strategies, Quality of Life, and Neurological Outcome in Patients Treated with Mechanical Thrombectomy after an Acute Ischemic Stroke

Silvia Reverté-Villarroya 1,2,*, Antoni Dávalos 3, Silvia Font-Mayolas 4,*, Marta Berenguer-Poblet 1,2,*, Esther Sauras-Colón 2, Carlos López-Pablo 1,2, Estela Sanjuan-Menéndez 5, Lucía Muñoz-Narbona 3, and Rosa Suñer-Soler 6

1 Department of Nursing, Rovira Virgili University, Campus Terres de l’Ebre, 43500 Tortosa, Spain; mberenguer.ebre.ics@gencat.cat (M.B.-P.); clopezp.ebre.ics@gencat.cat (C.L.-P.)
2 Hospital de Tortosa Verge de la Cinta, Pere Virgili Institut, 43500 Tortosa, Spain; esther.sauras@iispv.cat
3 RETICS Research Group, Department of Neurosciences, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Spain; adavalos.germanstrias@gencat.cat (A.D.); lmunoz@igtp.cat (L.M.-N.)
4 Quality of Life Institute, University of Girona, 17003 Girona, Spain; silvia.font@udg.edu
5 Stroke Unit, Hospital Universitari Vall d’Hebron, 08035 Barcelona, Spain; ensayosictus@gmail.com
6 Department of Nursing, University of Girona, 17003 Girona, Spain; rosa.sunyer@udg.edu
* Correspondence: silvia.reverte@urv.cat

Abstract: New reperfusion therapies have improved the clinical recovery rates of acute ischemic stroke patients (AISP), but it is not known whether other factors, such as the ability to cope, might also have an effect. The aim of this study was to evaluate the effect of endovascular treatment (EVT) on coping strategies, quality of life, and neurological and functional outcomes in AISP at 3 months and 1 year post-stroke. A multicenter, prospective, longitudinal, and comparative study of a sub-study of the participants in the Endovascular Revascularization with Solitaire Device versus Best Medical Therapy in Anterior Circulation Stroke within 8 Hours (REVASCAT) clinical trial was conducted after recruiting from two stroke centers in Catalonia, Spain. The cohort consisted of 82 ischemic stroke patients (n = 42 undergoing EVT and n = 40 undergoing standard best medical treatment (BMT) as a control group), enrolled between 2013–2015. We assessed the coping strategies using the Brief Coping Questionnaire (Brief-COPE-28), the health-related quality of life (HRQoL) with the EQ-5D questionnaire, and the neurological and functional status using the National Institute of Health Stroke Scale (NIHSS), Barthel Index (BI), modified Rankin Scale (mRS), and Stroke Impact Scale-16 (SIS-16). Bivariate analyses and multivariate linear regression models were used. EVT patients were the ones that showed better neurological and functional outcomes, and more patients presented reporting no pain/discomfort at 3 months; paradoxically, problem-focused coping strategies were found to be significantly higher in patients treated with BMT at 1 year.

Keywords: stroke; endovascular treatment; coping; health behavior; health-related quality of life

1. Introduction

The progress of medical treatments and urgent care strategies has evolved in recent decades, which has allowed for the survival rate of stroke patients to improve [1]. In addition, patients’ neurological involvement and functional dependence have been reduced and the life-changing consequences that affected people must cope with after a stroke have been improved [2].

The usual clinical practice has focused on assessing the sequelae after a stroke, but establishing the relationship between these sequelae and the functional impact is not a simple task and is little
quantified. Many patients with a stroke will also experience a reduced health-related quality of life (HRQoL) [2]. Known predictors of HRQoL are functional constraints, age, sex, socioeconomic status, depression, and coping strategies [3,4]. Thus, the quantification of the HRQoL, the disability grade, and the coping strategies is essential in treating patients after a stroke.

In recent decades, the contributions of health psychology in the field of cardiovascular diseases have gained special importance; these contributions take into account the adaptation of patients to their disease process and neurorehabilitation treatment, the adaptation to new derived lifestyles, and especially the attention to psychological needs generated by the disease status [5]. In this regard, the continuous study of psychological variables related to a patient’s health status will offer the possibility of carrying out specific interventions at a preventive level, as well as developing protective factors against diseases or strengthening healthy lifestyles [6,7].

Coping has been one of the major focuses of attention in the field of health psychology, based on the theoretical framework of Lazarus and Folkman (1984) [8], two of the main theorists of the coping study who defined it as “the constantly changing cognitive and behavioural efforts to manage the specific external or internal demands that are appraised as taxing or exceeding the resources of the person” [8]. Coping strategies, which are associated with a better HRQoL [9], have two major functions: dealing with the problem that is causing the distress (problem-focused coping) and regulating emotion (emotion-focused coping). After a stroke, patients use insufficient active problem-focused coping strategies [10].

Coping skills may be considered the key psychological resources necessary to rebuild the lives of patients disrupted by the residual deficits caused by a stroke. The possibility of adapting coping strategies that patients can use after a stroke could facilitate the design of better and more effective intervention strategies for these patients. However, to our knowledge and despite their significance, no studies have been published that explore the relationship between coping strategies in patients after an acute ischemic stroke treated with a thrombectomy. Thus, this research explores the possible relationship between coping styles, understood as the set of efforts that people make to face the problems and difficulties encountered in the environment and the subsequent stress that these situations generate, and the situation of disability that remains in patients who have suffered an acute ischemic stroke and received the most appropriate clinical treatment.

The main aim of this research was to study coping strategies, quality of life, and neurological and functional outcomes in a sample of patients at 3 months and 1 year after an ischemic stroke, who had been previously randomized and included in the Endovascular Revascularization with Solitaire Device versus Best Medical Therapy in Anterior Circulation Stroke within 8 Hours (REVASCAT) clinical trial [11] and classified in terms of the treatment received in the acute phase: either endovascular therapy (EVT, thrombectomy alone or with intravenous alteplase) or standard best medical treatment (BMT, intravenous alteplase or Stroke Unit admission).

2. Materials and Methods

2.1. Design

This was a multicenter, prospective, longitudinal, and comparative study between two groups: patients recovering from an anterior circulation proximal arterial occlusion stroke (1) treated with a Solitaire thrombectomy (EVT) or (2) treated with the standard best medical treatment (BMT) alone.

2.2. Participants

Patients were recruited as part of the REVASCAT clinical trial, the details of which were previously reported [11,12]. Briefly, in the REVASCAT, patients fulfilling the inclusion criteria were randomized into either of the treatment groups. This study was a sub-study of participants in the REVASCAT clinical trial. After consenting for our sub-study, 82 participants were enrolled from March 2013 to March 2015, with a follow-up until December 2016.
2.3. Measures and Instruments

Several sociodemographic variables were collected to study the sample characteristics. These variables included age, sex, medical history, and toxic habits (alcohol and smoking).

Brief Coping Questionnaire (Brief-COPE): The Spanish version of the Brief COPE (COPE-28) [13,14] was used to assess coping strategies at 3 months and 1 year after randomization by a researcher masked to the treatment allocation. COPE-28 is a scale that has 28 items to evaluate 14 dimensions through several questions that may be answered from “0 (I did not do this at all) to 3 (I did this a lot),” including intermediate scores. The higher the score obtained in each dimension, the greater the coping. The studied dimensions were active coping, planning, positive reframing, acceptance, humor, religion, emotional support, instrumental support, self-distraction, denial, venting, use of substances (alcohol or drugs), behavioral disengagement, and self-blame. In terms of psychometric characteristics, the alpha coefficients for this study were calculated at 3 months (\(\alpha = 0.75\)) and 1 year (\(\alpha = 0.68\)).

National Institute of Health Stroke Scale (NIHSS): The Spanish adapted version of the National Institute of Health Stroke Scale (NIHSS) was applied for the quantification of the neurological involvement. The NIHSS consists of 11 items, each of which provides information about neurological impairment. The score ranges on a scale between 0 and 42, 0 being evidence of normal function and 42 indicating a major neurological involvement (\(\alpha = 0.90\)) [15].

Barthel Index (BI): The Barthel Index (BI) has 10 questions about activities of daily life to assess the functional independence of stroke patients [16]. These questions are related to feeding, bathing, grooming, dressing, bowels, bladder, toilet use, transfers, mobility, and stairs, amounting to a total of 100 points. The higher the score obtained, the higher the level of functional independence (\(\alpha = 0.90–0.92\)) [17].

Modified Rankin Scale (mRS): The modified Rankin Scale (mRS) [18,19] was used in this study to quantify patients’ functional ability after a stroke. The scale goes from 0 (asymptomatic after a stroke) to 6 (death). An mRS score between 0 and 2 indicates independence in the functional capacity after a stroke (\(k_w = 0.78–0.93\)) [20].

Stroke Impact Scale-16 (SIS-16): The abridged and translated version of the Stroke Impact Scale-16 (SIS-16) [21] was applied to assess the impact of impairment on patients after a stroke. This scale comprises 16 items, in which a higher score means that the patient has a better status and a lower stroke impact. An SIS-16 score between 40 and 80 is associated with less impairment and stroke impact (\(\alpha = 0.83–0.90\)) [22].

EuroQoL (EQ-5D): The EQ-5D was designed by an interdisciplinary group of researchers from several European countries [23] and adapted to the Spanish language [24]. This questionnaire has two parts: the first one is a description of the generic health status with five dimensions (mobility, personal care, daily activities, pain/discomfort, and anxiety/depression), and the second one is the visual analog scale (EQ-VAS), where the patient quantifies their health status in a range between 0 and 100. In terms of psychometric characteristics, the alpha coefficient for this study was calculated at 3 months (\(\alpha = 0.891\)) and 1 year (\(\alpha = 0.838\)).

2.4. Ethics Statement

This study was approved by the Ethics Committee and written informed consent was obtained from all patients participating in the study. The ID protocol of the study was ICTO/2014. The study has no conflict of interest with the stent retriever commercial product (Covidien).

2.5. Data Analysis

Descriptive statistics were used to summarize patients’ characteristics and study different types of variables. To test the differences between groups, Student’s t-test and the Mann–Whitney U test were used for quantitative variables, depending on the normality of the data. A chi-squared test was used for qualitative variables. Changes in the COPE-28, mRS, and NIHSS scales at 3 months and
1 year after randomization were assessed through the Wilcoxon sign ranks test. In addition, multiple linear regression models were carried out to explain the HRQoL at 3 months and 1 year after a stroke. Statistical significance was established at $p$-value < 0.05 with 95% confidence intervals (CIs).

### 3. Results

The sociodemographic and clinical-pathological characteristics of patients are presented in Table 1. The age and sex of participants were similar in both the EVT and BMT groups, and there were no significant differences between groups in all the variables except for previous strokes.

#### Table 1. Sociodemographic and clinical-pathological characteristics of the patients.

| Sociodemographic and Clinical-Pathological Characteristics | Total ($n = 82$) | EVT ($n = 42$) | BMT ($n = 40$) | $p$-Value |
|-----------------------------------------------------------|-----------------|----------------|----------------|----------|
| Age (years)                                               | 67.60 (10.40)   | 66.76 (10.15)  | 68.47 (10.72)  | 0.406    |
| Sex (male)                                                | 43 (52.4)       | 23 (54.8)      | 20 (50)        | 0.204    |
| Medical history                                           |                 |                |                |          |
| Psychiatric history                                       | 11 (13.4)       | 8 (19)         | 3 (7.5)        | 0.128    |
| Hypertension                                              | 55 (67.1)       | 27 (64.3)      | 28 (70)        | 0.582    |
| Diabetes mellitus                                         | 22 (26.8)       | 12 (28.6)      | 10 (25)        | 0.715    |
| Dyslipidaemia                                             | 52 (63.4)       | 26 (61.9)      | 26 (65)        | 0.775    |
| Ischemic heart disease                                    | 42 (51.2)       | 20 (47.6)      | 22 (55)        | 0.504    |
| Cancer                                                    | 11 (13.4)       | 5 (11.9)       | 6 (15)         | 0.681    |
| Previous stroke                                           | 7 (8.5)         | 1 (2.4)        | 6 (15)         | 0.041    |
| Previous TIA                                              | 3 (3.7)         | 1 (2.4)        | 2 (5)          | 0.337    |
| Toxic habits                                              |                 |                |                |          |
| Alcohol                                                   |                 |                |                |          |
| Never                                                     | 65 (79.3)       | 33 (78.6)      | 32 (80)        | 0.786    |
| Moderate                                                  | 13 (15.9)       | 7 (16.7)       | 6 (15)         |          |
| Severe                                                    | 3 (3.7)         | 1 (2.4)        | 2 (5)          |          |
| Former                                                    | 1 (1.2)         | 1 (2.4)        | 0              |          |
| Smoking                                                   |                 |                |                | 0.661    |
| Never                                                     | 53 (64.6)       | 26 (61.9)      | 27 (67.5)      |          |
| Moderate                                                  | 11 (13.4)       | 6 (14.3)       | 5 (12.5)       |          |
| Excessive                                                 | 5 (6.1)         | 3 (7.1)        | 2 (5)          |          |
| Former                                                    | 13 (15.9)       | 7 (16.7)       | 6 (15)         |          |

Values in brackets for age are standard deviations and are percentages for all the other values of the sample. BMT: Best Medical Treatment, EVT: Endovascular Treatment.

We assessed the stroke patients’ coping strategies with the COPE-28 scale after randomization and found that active coping at 3 months and acceptance and use of emotional support at 3 months and 1 year to be the dimensions with higher scores (Table 2). Notwithstanding, the BMT group had the most average scores higher than those in the EVT group at 1 year after randomization, with the exception of the religion and humor dimensions. Importantly, the only significant differences in the scores between the patients’ groups were those recorded in active coping and acceptance ($p = 0.03$ and $p = 0.034$, respectively; Table 2).
Table 2. Brief Coping Questionnaire (COPE-28) Scale at 3 months and 1 year after randomization, depending on the group treatment.

| COPE-28 Items                      | Total (n = 50) | COPE-28 (3 Months) | p-Value | COPE-28 (1 Year) | p-Value |
|-----------------------------------|---------------|--------------------|---------|------------------|---------|
| Active coping EVT: 23             | 3.92 [1.99]   | 0.267              | 3.63 [2.10] | 0.030 |
| Items 2 and 10 BMT: 27            | 4.52 [1.83]   |                     | 4.74 [1.43] |         |
| Planning EVT: 23                  | 2.96 [1.88]   | 0.465              | 2.79 [2.10] | 0.637 |
| Items 6 and 26 BMT: 27            | 3.37 [2.10]   |                     | 3.07 [2.13] |         |
| Use of emotional support EVT: 23  | 3.92 [2.30]   | 0.753              | 4.25 [2.07] | 0.597 |
| Items 9 and 17 BMT: 27            | 4.11 [2.08]   |                     | 4.56 [2.03] |         |
| Social support EVT: 23            | 3.04 [1.76]   | 0.195              | 3.21 [1.64] | 0.458 |
| Items 1 and 28 BMT: 27            | 3.67 [1.64]   |                     | 3.59 [1.99] |         |
| Religion EVT: 23                  | 1.79 [2.32]   | 0.574              | 2.50 [2.54] | 0.403 |
| Items 16 and 20 BMT: 27           | 1.44 [2.06]   |                     | 1.93 [2.32] |         |
| Positive reframing EVT: 23        | 2.54 [2.18]   | 0.886              | 2.83 [1.99] | 0.164 |
| Items 14 and 18 BMT: 27           | 2.63 [2.15]   |                     | 3.63 [2.02] |         |
| Acceptance EVT: 23                | 4.21 [1.79]   | 0.795              | 4.25 [1.65] | 0.034 |
| Items 3 and 21 BMT: 27            | 4.33 [1.62]   |                     | 5.00 [1.39] |         |
| Denial EVT: 23                    | 1.17 [1.63]   | 0.441              | 0.92 [1.25] | 0.339 |
| Items 5 and 13 BMT: 27            | 1.56 [1.91]   |                     | 1.33 [1.75] |         |
| Humor EVT: 23                     | 1.33 [1.93]   | 0.944              | 1.29 [1.85] | 0.830 |
| Items 7 and 19 BMT: 27            | 1.37 [1.82]   |                     | 1.19 [1.67] |         |
| Self-distraction EVT: 23          | 3.00 [2.04]   | 0.499              | 2.75 [1.87] | 0.299 |
| Items 4 and 22 BMT: 27            | 2.59 [2.21]   |                     | 3.33 [2.08] |         |
| Self-blame EVT: 23                | 1.29 [1.57]   | 0.945              | 1.33 [1.50] | 0.548 |
| Items 8 and 27 BMT: 27            | 1.26 [1.77]   |                     | 1.63 [1.95] |         |
| Behavioral disengagement EVT: 23  | 1.33 [1.69]   | 0.728              | 0.71 [1.08] | 0.463 |
| Items 11 and 25 BMT: 27           | 1.19 [1.33]   |                     | 0.96 [1.34] |         |
| Venting EVT: 23                   | 1.25 [1.26]   | 0.496              | 1.54 [1.50] | 0.906 |
| Items 12 and 23 BMT: 27           | 1.52 [1.50]   |                     | 1.59 [1.55] |         |
| Substance abuse EVT: 23           | 0.21 [0.66]   | 0.202              | 0.13 [0.61] | 0.697 |
| Items 15 and 24 BMT: 27           | 0.04 [0.19]   |                     | 0.19 [0.48] |         |

Variables are represented as median [IQR].

All the scales evaluated in this study describe neurological deficits and functional capacity before and after a stroke. Although the NIHSS score at baseline was not statistically significant between groups, the score was significantly different at 24 h after randomization, showing greater neurological involvement in the EVT group (Table 3). All the participants in this study were autonomous in their activities of daily life before their stroke (BI = 100) and presented favorable functional capacities, as shown by the mRS test (0–2). Although the functional status at 3 months and 1 year was greater in the EVT group, as shown by higher values in the BI, mRS, and SIS-16 scales, the difference between groups was not statistically significant (Table 3).
Table 3. Neurological and functional outcome of patients: post-treatment, at 3 months, and 1 year after a stroke.

| Neurological and Functional Scales | Total (n = 82) | EVT (3 Months; n = 42) | EVT (1 Year; n = 35) | BMT (3 Months; n = 35) | BMT (1 Year; n = 31) | p-Value |
|----------------------------------|---------------|------------------------|----------------------|------------------------|----------------------|---------|
| Baseline NIHSS                   | 16 [13–19]    | 15 [11–19]             | 17 [14–19]           | 0.225                  |
| NIHSS 24 h                       | 10 [4–15]     | 6 [3–13]               | 11 [7–17]            | 0.013                  |
| NIHSS 3 months                   | 7 [1–11]      | 2 [1–12]               | 5 [3–11]             | 0.071                  |
| NIHSS 1 year                     | 5 [1–7]       | 4 [0–8]                | 6 [1–7]              | 0.484                  |
| Previous BI                      | 100           | 100                    | 100                  | 1.000                  |
| BI 3 months                      | 80 [10–98]    | 80 [13–100]            | 70 [10–95]           | 0.184                  |
| BI 1 year                        | 76 [60–100]   | 78 [65–100]            | 74 [60–95]           | 0.336                  |
| Previous mRS                     | 0 [0–0]       | 0 [0–0]                | 0 [0–1]              | 0.355                  |
| mRS 3 months                     | 3 [2–5]       | 2 [2–5]                | 3 [2–5]              | 0.178                  |
| mRS 1 year                       | 3 [2–3]       | 2 [2–3]                | 3 [2–3]              | 0.536                  |
| SIS-16 3 months                  | 53 [21–73]    | 59 [22–75]             | 48 [16–70]           | 0.269                  |
| SIS-16 1 year                    | 57 [46–76]    | 60 [53–78]             | 54 [37–71]           | 0.178                  |

Variables are represented with median [IQR]. BI: Barthel Index, mRS: Modified Rankin Scale, NIHSS: National Institute of Health Stroke Scale, SIS-16: Stroke Impact Scale-16.

We performed the categorization of the NIHSS, mRS, BI, and SIS-16 scales according to the score intervals considered to indicate favorable functional and neurological statuses in order to assess which of the treated groups had a more favorable functional and neurological performance. Although the percentages of favorable evolution in all the tests were higher in the EVT group at 3 months and 1 year after randomization, only the mRS at 3 months proved to be statistically significant (Table 4).

Table 4. The number of patients included in the favorable functional and neurological category of the evaluated scales at 3 months and 1 year after a stroke.

| Neurological and Functional Scales | 3 Months | 1 Year | p-Value |
|----------------------------------|----------|--------|---------|
| NIHSS [0–2]                      | EVT (n = 42) | BMT (n = 40) | 0.314 | 17 (60.7) | 14 (53.8) | 0.876 |
| mRS [0–2]                        | EVT (n = 35) | BMT (n = 31) | 0.029 | 20 (47.6) | 11 (27.5) | 0.119 |
| BI [95–100]                      | EVT (n = 35) | BMT (n = 31) | 0.881 | 17 (65.4) | 13 (52) | 0.332 |
| SIS-16 [40–80]                   | EVT (n = 35) | BMT (n = 31) | 0.585 | 28 (80) | 23 (74.2) | 0.574 |

Variables are represented with number of cases (percentage).

Furthermore, the HRQoL was quantified using the EQ-5D scale at 3 months and 1 year after a stroke (Table 5). Importantly, the dimension related to pain/discomfort was the only one to show significant differences between the two groups at 3 months. Indeed, the EVT group had a higher percentage of people without pain or discomfort. In addition, the median total score obtained by the EQ-VAS was higher in this group than in the BMT group (60 vs. 50), with a clear trend toward significance (p = 0.053).

Finally, the results of a multivariate analysis at 3 months after a stroke showed that the variables associated with HRQoL (EQ-VAS) were the EVT (p = 0.038), functional status evaluated using the mRS scale (p < 0.001), and the pain/discomfort dimension in the EQ-5D scale (p < 0.001) (Table 6).
Table 5. The health-related quality of life (HRQoL) perceived by participants at 3 months and 1 year after a stroke.

| HRQoL                        | EVT 3 Months (n = 40) | BMT 3 Months (n = 36) | p-Value | EVT 1 Year (n = 35) | BMT 1 Year (n = 31) | p-Value |
|------------------------------|-----------------------|-----------------------|---------|---------------------|---------------------|---------|
| Mobility                     |                       |                       | 0.204   |                     |                     | 0.635   |
| I have no trouble walking    | 21 (52.5)             | 12 (33.3)             |         | 18 (51.4)           | 13 (41.9)           |         |
| I have some trouble walking  | 11 (27.5)             | 16 (44.4)             |         | 12 (33.3)           | 14 (43.2)           |         |
| I have to stay in bed        | 8 (20)                | 8 (22.2)              |         | 5 (14.3)            | 4 (12.9)            |         |
| Personal care                |                       |                       | 0.129   |                     |                     | 0.514   |
| I have no problems with personal care | 21 (52.5) | 12 (33.3) |         | 20 (57.1)           | 14 (43.2)           |         |
| I have some difficulty in washing or dressing myself | 7 (17.5)     | 13 (36.1)         |         | 7 (20)              | 10 (32.3)           |         |
| I am unable to wash or dress myself | 12 (30)     | 11 (30.6)         |         | 8 (22.9)            | 7 (22.6)            |         |
| Daily activities             |                       |                       | 0.645   |                     |                     | 0.792   |
| I have no problems           | 12 (30)               | 8 (22.2)              |         | 10 (28.6)           | 8 (25.8)            |         |
| I have some problems         | 15 (37.5)             | 13 (36.1)             |         | 13 (37.1)           | 13 (41.9)           |         |
| I am unable to do daily activities | 13 (32.5) | 15 (41.7)         |         | 12 (34.3)           | 10 (32.3)           |         |
| Pain/discomfort              |                       |                       | 0.012   |                     |                     | 0.426   |
| I have no pain or discomfort | 22 (55)               | 10 (27.8)             |         | 17 (48.6)           | 11 (35.5)           |         |
| I have moderate pain or discomfort | 11 (27.5) | 22 (61.1)         |         | 14 (40)             | 13 (41.9)           |         |
| I have a lot of pain or discomfort | 7 (17.5)   | 4 (11.1)           |         | 4 (11.4)            | 7 (22.6)            |         |
| Anxiety/depression           |                       |                       | 0.838   |                     |                     | 0.797   |
| I am not anxious or depressed | 13 (32.5)          | 10 (27.8)             |         | 12 (34.3)           | 12 (38.7)           |         |
| I am moderately anxious or depressed | 20 (50)      | 18 (50)           |         | 18 (51.4)           | 15 (48.4)           |         |
| I am very anxious or depressed | 7 (17.5)        | 8 (22.2)           |         | 5 (14.3)            | 4 (12.9)            |         |
| EQ-SD index                  | 0.760 (0.177)         | 0.692 (0.150)         | 0.078   | 0.763 (0.160)       | 0.731 (0.167)       | 0.440   |
| EQ-VAS (0–100)               | 60 [40–75]            | 50 [21–70]            | 0.053   | 58 [30–75]          | 56 [40–80]          | 0.707   |

The EuroQoL visual analog scale (EQ-VAS) is represented as median [IQR], while the rest of the variables are shown with the number of cases (percentage).

Table 6. Variables associated with the HRQoL (EQ-VAS) at 3 months after a stroke.

| Variable                        | B         | Standard Error | β       | p-Value (CI 95%) |
|---------------------------------|-----------|----------------|---------|-----------------|
| Constant                        | 1.013     | 0.065          | 0.000   | 0.883           | 1.143           |
| Age                             | 0.001     | 0.001          | 0.049   | 0.400           | −0.001          | 0.003           |
| Sex                             | −0.015    | 0.018          | 0.046   | 0.405           | −0.052          | 0.021           |
| Treatment (EVT)                 | 0.039     | 0.019          | 0.118   | 0.038           | 0.002           | 0.077           |
| NIHSS                           | 0.003     | 0.002          | 0.129   | 0.110           | −0.001          | 0.007           |
| mRS                             | −0.078    | 0.009          | −0.739  | 0.000           | −0.096          | −0.061          |
| Pain/discomfort dimension (EQ-SD) | −0.078  | 0.016          | −0.330  | 0.000           | −0.111          | −0.046          |

Adjusted $R^2 = 0.563$.

At 1 year after a stroke, the variables associated with HRQoL (EQ-VAS) were functional status assessed using the mRS scale ($p < 0.001$) and the pain dimension in the EQ-5D scale ($p < 0.001$) (Table 7). In both analyses, the score on the mRS scale and pain/discomfort dimension was inversely related to the HRQoL ($β = −0.739$ and $β = −0.330$ at 3 months and $β = −0.595$ and $β = −0.441$ at 1 year). The multiple linear regression models accounted for 56% of the HRQoL variability at 3 months and 53% at 1 year, respectively (Tables 6 and 7).
Table 7. Variables associated with the HRQoL (EQ-VAS) at 1 year after a stroke.

| Variable                        | B      | Standard Error | β     | p-Value (CI 95%) | Lower Limit | Upper Limit |
|---------------------------------|--------|----------------|-------|-----------------|-------------|-------------|
| Constant                        | 1.063  | 0.066          | 0.000 | 0.930           | 0.930       | 1.195       |
| Age                             | 0.001  | 0.001          | 0.059 | 0.319           | −0.001      | 0.003       |
| Sex                             | −0.016 | 0.019          | −0.050| 0.393           | −0.054      | 0.021       |
| Treatment (EVT)                 | −0.131 | 3.566          | −0.033| 0.971           | −7.266      | 7.004       |
| NIHSS                           | −0.001 | 0.003          | −0.023| 0.805           | −0.006      | 0.004       |
| mRS                             | −0.070 | 0.011          | −0.595| 0.000           | −0.092      | −0.048      |
| Pain/discomfort dimension (EQ-5D)| −0.099 | 0.014          | −0.441| 0.000           | −0.127      | −0.070      |

Adjusted $R^2 = 0.536$.

4. Discussion

From the evidence of the EVT efficacy, the therapeutic approach for patients with ischemic stroke has changed drastically [25]. Most previous research on the treatment of patients with ischemic stroke has focused on the improvement of patients’ neurological and functional aspects, whereas there is little research approaching the psychological sphere that studies coping strategies [26,27]. Nevertheless, the aforementioned studies do not present an accurately selected sample (as there are no selection criteria), and they are cross-sectional studies without self-reported questionnaires and with short follow-ups (<6 months) [27].

This is the first study to investigate the coping strategies of patients in the acute phase of stroke recovery based on the received treatment (EVT or BMT) in a randomized sample. Our results show that patients with ischemic stroke that were treated with either the EVT or BMT in the acute phase presented similar coping strategies at 3 months after a stroke. Nevertheless, 1 year after a stroke, patients treated with the BMT showed significantly higher scores in active coping and acceptance dimensions, which belong to problem-focused coping strategies. This suggests that patients recovering from an acute stroke after being treated with the BMT have more positive attitudes toward the condition, and therefore, take actions such as acceptance of the illness and finding solutions to improve their status [10,28].

Our results are consistent with previous research in which problem-focused coping strategies were reported more often than emotion-focused coping strategies in stroke patients [29]. It has also been observed that problem-focused, active coping strategies improve psychological outcomes in people with chronic illnesses, noting that cultivating a tendency to relate to oneself with kindness, compassion, and acceptance (self-compassion) is related to active coping strategies and can be valuable in reducing stress for those facing a chronic situation [30].

Furthermore, emotion-focused coping strategies have previously been associated with a worse stroke recovery [31,32]. Feelings of guilt, anger, and sadness are negative emotions that can arise after suffering an unexpected or uncontrollable and functionally limiting event, such as a stroke. Avoiding facing up to the illness is associated with poor results; it generates helplessness and therefore less acceptance of it. All of this can contribute to recurrent additional stress that prevents the development of healthy behaviors [29,30,32].

With regard to patients’ quality of life, the EVT group presented a higher number of patients with no pain/discomfort than the BMT group, and in turn, obtained higher scores in the analogical part of the EQ-5D scale, especially in the short term [33]. Indeed, this is in line with previous studies that indicated that patients with a chronic illness that have few but self-perceived effective coping strategies may have a more positive effect on the HRQoL than patients using other types of strategies targeting each individual’s personal resources, such as a lower sense of coherence [34]. A sense of coherence implies that the patient understands the magnitude of their illness, the degree of motivation to cope
with it, and their ability to manage what this involves, which could influence coping strategies, and as a result, the impact on their quality of life [34].

Thus, encouraging patients to adopt coping strategies is a complex process because it involves the patient adopting self-management behaviors, exercising self-control of their processes and results, and actively participating in their health education, although there is limited evidence of the effect of psychosocial interventions in stroke patients that can improve the results in terms of their quality of life [35–37]. Therefore, effective coping should be based on using a set of coping strategies that enable stress management in the context of the illness and switching to new adaptive strategies as the situation evolves [30].

Our findings suggest that these factors should be taken into account to promote better interventions with regard to the secondary prevention for these patients and improve their HRQoL, leaving an open door for future investigations. While the technology associated with interventional strategies is improving and technical outcomes are also improving, longer-term outcomes may not be [36,37].

Although the EVT patients’ group was associated with a better HRQoL and presented a more favorable neurological and functional status compared to the BMT group, paradoxically, they did not show better coping strategies in the short term (3 months), nor in the long term (1 year) after a stroke. This could be due to the better functional and neurological outcome of the EVT patients, who showed less clinical involvement, and therefore, less perception and awareness of the illness, entailing less coping and acceptance by patients. Although this finding is revealing, it is currently difficult to discuss since there are no studies that incorporate the coping process into the assessment of the patient’s neurological and physical status, or that allow for a predictive relationship to be made between these variables.

Finally, we found the EVT to be positively associated with the HRQoL; meanwhile, pain/discomfort and functional outcomes were inversely associated at 3 months, but not at one year after having the stroke in our patient cohort [35]. This may be explained by the fact that patients undergoing the EVT reported better short- and long-term quality of life scores, and in turn, better neurological and functional statuses. A study has been published recently that reinforces how the EVT in people who have suffered a stroke has a favorable impact on the patients’ quality of life. However, coping and other variables related to their adaptation to a diagnosis of stroke have not been studied [38]. In line with this, we found similar results regarding neurological outcomes and functional capacities to those obtained in the whole population studied in the REVASCAT [39–41], indicating that the variables analyzed in this study can be generalized to the totality of people with acute ischemic stroke currently treated with the EVT.

Limitations of the Study and Future Research

Although the results obtained from our study can be extrapolated to the rest of the population meeting the same criteria, we found that the neurological status led to a loss of follow-up. Hence, there was a reduction in the number of patients answering the COPE scale at 3 months and 1 year, and the other scales at 1 year. Another limitation was that no specific variables or constructs related to positive and adaptive coping strategies (such as personal abilities) and attitudes (such as resilience and self-compassion) or mediating variables (such as dispositional optimism associated with stress reduction) were studied. Therefore, future research on how people who have suffered a stroke, in addition to containing the variables studied, should include other study factors, which would allow for a greater understanding of the process and follow-up, including examining the care received and the environment of those affected.

Author Contributions: Conceptualization, S.R.-V., R.S.-S., A.D., and S.F.-M.; methodology, S.R.-V., R.S.-S., A.D., and S.F.-M.; formal analysis, S.R.-V., R.S.-S., E.S.-C., and C.L.-P.; investigation, S.R.-V., R.S.-S., A.D., and S.F.-M.; resources, S.R.-V., E.S.-M. and L.M.-N.; data curation, S.R.-V., R.S.-S., S.F.-M., E.S.-C., and C.L.-P.; writing—original draft preparation, S.R.-V., A.D., R.S.-S., S.F.-M., M.B.-P., E.S.-C., and C.L.-P.; writing—review and editing, S.R.-V., A.D., R.S.-S., S.F.-M., M.B.-P., E.S.-C., C.L.-P., E.S.-M., and L.M.-N.; funding acquisition, S.R.-V. All authors have read and agreed to the published version of the manuscript.
**Funding:** This research was funded by Fundació Dr. Ferran, grant number PSI-5930.

**Acknowledgments:** The authors would like to thank all participating patients and the Department of Neuroscience University Germans Trias Pujol and University Hospital Vall d’Hebron, Spain.

**Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

**References**

1. Falk-Delgado, A.; KuntzeSoderqvist, A.; Fransen, J. Improved clinical outcome 3 months after endovascular treatment, including thrombectomy, in patients with acute ischemic stroke: A meta-analysis. *J. Neurointerv. Surg.* 2016, 8, 665–670. [CrossRef] [PubMed]

2. Ramos-Lima, M.J.M.; Brasileiro, I.; Lima, T.L.; Braga-Neto, B. Quality of life after stroke: Impact of clinical and sociodemographic factors. *Clinics* 2018, 73. [CrossRef] [PubMed]

3. Almborg, A.H.; Ulander, K.; Thulin, A.; Berg, S. Discharged after stroke-important factors for health-related quality of life. *J. Clin. Nurs.* 2010, 19, 2196–2206. [CrossRef] [PubMed]

4. Tielemans, N.S.; Scheipers, V.P.; Visser-Meily, J.M.; Post, M.W.; van Heugten, C.M. Associations of proactive coping and self-efficacy with psychosocial outcomes in individuals after stroke. *Arch. Phys. Med. Rehabil.* 2015, 96, 1484–1491. [CrossRef] [PubMed]

5. Van Rijsbergen, M.W.A.; Mark, R.E.; Kop, W.J.; Kort, P.L.M.; Sitskoorn, M.M. Course and predictors of subjective cognitive complaints during the first 12 months after stroke. *J. Stroke Cerebrovasc. Dis.* 2020, 29, 1–9. [CrossRef]

6. Díaz-Tapia, V.; IllanesDiez, S.; Gana, J.; Sobarzo, M.; Jaramillo-Muñoz, A. Estudio sobre la calidad de vida en pacientes con accidente vascular cerebral isquémico. *Rev. Neurol.* 2008, 46, 652–655. [CrossRef]

7. Dewilde, S. The combined impact of dependency on caregivers, disability, and coping strategy on quality of life after ischemic stroke. *Health Qual. Life Outcomes* 2019, 17, 1–11. [CrossRef]

8. Lazarus, R.S.; Folkman, S. *Stress, Appraisal, and Coping*, 1st ed.; Springer Electronic Books: New York, NY, USA, 1984.

9. Yu, J.; Hu, J.; Efird, T.; McCoy, T.P. Social support, coping strategies and health-related quality of life among primary caregivers of stroke survivors in China. *J. Clin. Nurs.* 2013, 22, 2160–2171. [CrossRef]

10. Folkman, S.; Lazarus, R.S.; Gruen, R.J.; Delongis, A. Appraisal, coping, health status, and psychological symptoms. *J. Pers. Soc. Psychol.* 1986, 50, 571–579. [CrossRef]

11. Jovin, T.G.; Chamorro, A.; Cobo, E.; Miquel, M.A.; Molina, A.; Rovira, A.; Luis San Román, M.D.; Joaquín Serena, M.D.; Sonia Abilleira, M.D.; Ribo, M.; et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. *N. Engl. J. Med.* 2015, 372, 2296–2306. [CrossRef]

12. Molina, C.A.; Chamorro, A.; Rovira, A.; Miquel, A.; Serena, J.; San Roman, L.; Jovin, T.G.; Davalos, A.; Cobo, E. REVASCAT: A randomized trial of revascularization with SOLITAIRE FR® device vs. best medical therapy in the treatment of acute stroke due to anterior circulation large vessel occlusion presenting within eight-hours of symptom onset. *Int. J. Stroke* 2015, 10, 619–626. [CrossRef] [PubMed]

13. Carver, C.S. You want to measure coping but your protocol’s too long: Consider the brief COPE. *Int. J. Behav. Med.* 1997, 4, 92–100. [CrossRef]

14. Morán, C.; Landero, R.; González, M.T. COPE-28: Un análisis psicométrico de la versión en español del Brief COPE. *Univ.Psychol.* 2010, 9, 543–552. [CrossRef]

15. Montaner, J.; Alvarez-Sabin, J. NIH stroke scale and its adaptation to Spanish. *Neurologia* 2006, 4, 192–202.

16. Cid-Ruzafa, J.; Damián-Moreno, J. Valoracion de la discapacidad fisica: El Indice de Barthel. *Rev. Esp. Salud Publ.* 1997, 71, 127–137. [CrossRef]

17. Shah, S.; Vanclay, F.; Cooper, B. Improving the sensitivity of the Barthel index for stroke Rehabilitation. *J.Clin. Epidemiol.* 1989, 42, 703–709. [CrossRef]

18. Hong, K.S.; Saver, J.L. Quantifying the value of stroke disability outcomes: Who global burden of disease project disability weights for each level of the modified rankin scale. *Stroke* 2009, 40, 3828–3833. [CrossRef] [PubMed]

19. Rankin, J. Cerebral vascular accidents in patients over the age of 60: II. Prognosis. *Scott. Med. J.* 1957, 2, 200–215. [CrossRef] [PubMed]
20. Wilson, J.T.L.; Hareendra, A.; Grant, M.; Baird, T.; Schulz, U.G.R.; Muir, K.; Bone, I. Improving the assessment of outcomes in stroke: Use of a structured interview to assign grades on the modified Rankin Scale. Stroke 2002, 33, 2243–2246. [CrossRef]

21. Duncan, P.W.; Wallace, D.; Lai, S.M.; Johnson, D.; Embretson, S.; Laster, L.J. The stroke impact scale version 2.0: Evaluation of reliability, validity, and sensitivity to change. Stroke 1999, 30, 2131–2140. [CrossRef]

22. Palomino-Aguado, B. Contribución De La Adaptación Y Validación De La Escala Sis-16 (StrokeImpactScale) En El Manejo De La Rehabilitación De Pacientes Con Ictus: Memoria Para Optar Al Grado De Doctor En Medicina; Universidad Complutense de Madrid: Madrid, Spain, 2010.

23. EuroQolGroup. EQ-5D-5L User Guide. Basic Information on How to Use the EQ-5D-5L Instrument. 2011. Available online: http://www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Folders_Flyers/UserGuide_EQ-5D-5L.pdf (accessed on 13 June 2020).

24. Badia, X.; Roset, M.; Montserrat, S.; Herdman, M.; Segura, A. The Spanish version of EuroQol: A description and its applications. Med. Clin. 1999, 112, 79–85.

25. Alonso de Leciñana, M.; Mazya, M.V.; Kostulas, N.; del Brutto, O.H.; Abanto, C.; Massaro, A.R.; de Bastos, M.; Martins, S.; Ameriso, S.; Gongora-Rivera, F.; et al. Stroke Care and Application of Thrombolysis in Ibero-America: Report From the SITS-SIECV Ibero-American Stroke Register. Stroke 2019, 50, 1–6. [CrossRef]

26. Van Mierlo, M.; van Heugten, C.; Post, M.; Hoeksstra, T.; Visser-Meily, A. Trajectories of health-related quality of life after stroke: Results from a one-year prospective cohort study. Disabil. Rehabilit. 2017, 40, 997–1006. [CrossRef]

27. Lo Buono, V.; Corallo, F.; Bramanti, P.; Marino, S. Coping strategies and health-related quality of life after stroke. J. Health Psychol. 2017, 22, 16–28. [CrossRef] [PubMed]

28. Lazarus, R.S.; Valdés, M.; Folkman, S. Estrés Y Procesos Cognitivos, 1st ed.; Roca, M., Ed.; Barcelona: Barcelona, Spain, 1986.

29. Donnellan, C.; Hevey, D.; Hickey, A.; O’Neill, D. Defining and quantifying coping strategies after stroke: A review. J. Neurol. Neurosurg. Psychiatry 2006, 77, 1208–1218. [CrossRef] [PubMed]

30. Sirois, F.; Molnar, D.; Hirsch, J. Self-compassion, stress, and coping in the context of chronic illness. Self Ident. 2015, 14, 334–347. [CrossRef]

31. Tramonti, F.; Fanciullacci, C.; Giunti, G.; Rossi, B.; Chisari, C. Functional status and quality of life of stroke survivors undergoing rehabilitation programmes in a hospital setting. Neuro. Rehabilit. 2014, 35, 1–7. [CrossRef]

32. Lyon, B.L. Psychological stress and coping: Framework or poststroke psychological care. Top Stroke Rehabil. 2002, 9, 1–15. [CrossRef]

33. Gomez-Bernal, F.; Madva, E.; Puckett, J.; Amonoo, H.; Millstein, R.; Huffman, J. Relationships between life stressors, health behaviors, and chronic medical conditions in mid-life adults: A narrative review. Psychosomatics 2019, 60, 153–163. [CrossRef]

34. Kristofferzon, L.; Engström, M.; Nilsson, A. Coping mediates the relationship between sense of coherence and mental quality of life in patients with chronic illness: A cross-sectional study. Qual. Life Res. 2018, 27, 1855–1863. [CrossRef]

35. Visser, M.; Heijenbrok-Kal, M.H.; Spijker, A.; Lannoo, E.; Busschbach, J.J.V.; Ribbers, G.M. Problem-solving therapy during outpatient stroke rehabilitation improves coping and health-related quality of life. Stroke 2016, 47, 135–142. [CrossRef] [PubMed]

36. Lin, S.; Dongxia, L.; Chamberlain, D.; Newman, P.; Xie, S. The effect of transition care interventions incorporating health coaching strategies for stroke survivors: A systematic review and meta-analysis. Patient Educ. Couns. 2020. [CrossRef] [PubMed]

37. Minshall, C.; Castle, D.; Thompson, D.; Pascoe, M.; Cameron, J.; McCabe, M.; Apputhurai, P.; Knowles, S.; Jenkins, Z.; Ski, C. A psychosocial intervention for stroke survivors and carers: 12-month outcomes of a randomized controlled trial. Topics Stroke Rehab. 2020. [CrossRef] [PubMed]

38. Deb-Chatterji, M.; Konnopka, A.; Flottmann, F.; Leischener, H.; Fiehler, J.; Gerloff, C.; & Thomalla, G. Patient-reported health-related quality of life after stroke thrombectomy in clinical practice. Neurology 2020. [CrossRef]
39. Millán, M.; Remollo, S.; Quesada, H.; Renú, A.; Tomasello, A.; Minhas, P.; Perez de la Ossa, N.; Rubiera, M.; Llull, L.; Cardona, P.; et al. Vessel Patency at 24 hours and its relationship with clinical outcomes and infarct volume in revascat trial (randomized trial of revascularization with solitaire fr device versus best medical therapy in the treatment of acute stroke due to anterior circulation large vessel occlusion presenting within eight hours of symptom onset). *Stroke* 2017, 48, 983–989. [CrossRef]

40. López-Cancio, E.; Jovin, T.D.; Cobo, E.; Cerdá, N.; Jiménez, M.; Gomis, M.; Hernández-Pérez, M.; Cáceres, C.; Cardona, P.; Blanca, L.; et al. Endovascular treatment improves cognition after stroke. *Neurology* 2017, 88, 245–251. [CrossRef]

41. Dávalos, A.; Cobo, E.; Molina, C.; Chamorro, A.; Miquel, M.A.; San Román, L.; Joaquin, S.; Lopez-Canio, E.; Ribo, M.; Milan, M.; et al. Safety and efficacy of thrombectomy in acute ischaemic stroke (REVASCAT): 1-year follow-up of a randomised open-label trial. *Lancet Neurol.* 2017, 16, 369–376. [CrossRef]